Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. - Wikidata - wikimedia - TriplyDB

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.

http://www.wikidata.org/entity/Q35655989

about

The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate Therapeutic approaches for celiac disease Environmental Enteric Dysfunction in Children.Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Current Status of Celiac Disease Drug Development.Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model.The complex task of measuring intestinal permeability in basic and clinical science.Current and novel therapeutic strategies in celiac disease.Systematic review: patient-reported outcome measures in coeliac disease for regulatory submissions.Celiac Disease: Role of the Epithelial Barrier.Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Protective Effect of 1,25-Dihydroxy Vitamin D3 on Pepsin-Trypsin-Resistant Gliadin-Induced Tight Junction Injuries.Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet.Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.Abnormal Barrier Function in Gastrointestinal Disorders.Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study.

P2860

Q26771888-8C553F9A-0C03-4433-88B8-CEDD8036D3D9 Q26825413-94C0918D-7C62-44EA-B0B6-E48EB7F45156 Q37037319-1F033E29-D743-4EBC-997A-0630C00AEB2D Q38515695-70E259AD-9A40-48CF-B7A5-1383AA7C9687 Q38791641-C072A4F7-5654-4D39-9D58-AADBBF6DB22E Q38830164-8EAE4EB1-271E-43C9-8E62-82681B4ACB1B Q38849031-D93C9EC5-3F82-4353-AE45-EA03EFB5EA8C Q38870456-7D8D4D9D-4EDF-411C-BE8C-359CF7F0D769 Q38878748-66024A8F-1E14-43C4-BED7-040647AC53CE Q38919389-6C5945C2-8807-411E-BF4F-DC1F8F4489D6 Q39103865-69861799-7DBF-49DF-BFA3-F038DD995D48 Q42695148-648DB5ED-AFE4-44B5-917B-28F45C742103 Q47856590-B54792BA-4779-4451-A424-B169CFAD2852 Q47867778-BE0E3BC9-44E3-48C5-A316-BF94AA64FF31 Q50063465-21F7A0E1-103E-4836-81BA-39594F4968C7 Q50220919-74398B96-D7EA-475C-BC39-B03CE7527737 Q50350904-695977D0-9973-4D2A-8F2E-5F7B704D7C89

P2860

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.

http://www.wikidata.org/entity/Q35655989

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Larazotide acetate for persist ...... a randomized controlled trial.

@ast

Larazotide acetate for persist ...... a randomized controlled trial.

@en

type

label

Larazotide acetate for persist ...... a randomized controlled trial.

@ast

Larazotide acetate for persist ...... a randomized controlled trial.

@en

prefLabel

Larazotide acetate for persist ...... a randomized controlled trial.

@ast

Larazotide acetate for persist ...... a randomized controlled trial.

@en

P1433

Q35655989-EE561F85-906F-4310-86C4-A79A134F1866

P1476

Q35655989-A6C51270-C686-483D-B13F-B0DA54EB4DD4

P2093

Q35655989-60AEF4C0-3EE3-4258-A598-C48DF55482FA

Q35655989-756F398B-F6B1-4993-BF7F-C9F15D67355E

Q35655989-887BACAD-C2F8-4EDD-8C59-2105A3E8E9AE

Q35655989-A4B68482-036C-4F33-BE25-EC3570C0647B

Q35655989-A771EEA5-5B0A-42B2-AED7-456775019AC6

Q35655989-C5D2DE2A-7823-44D5-9175-E5E19FB892A3

Q35655989-CC0889A3-60EB-40C0-92EA-18946DC8715B

Q35655989-DE865BC3-E890-45F0-9388-49EDAD5361A3

Q35655989-DFF33D3B-3DD7-431B-A742-DEAEF4B069E1

Q35655989-E0A42D58-79B6-43F2-9E8B-908930199FE4

P2860

Q35655989-00DF5017-88B2-4C5A-8679-E6EDFB3796C3

Q35655989-0997D2BA-70B8-4B16-A25F-50CA007954B7

Q35655989-0BB03B24-83E5-402A-A235-2A7BE9B8A032

Q35655989-0CC26A8A-2BAD-4C88-83E5-0C4B07898679

Q35655989-158AC522-F56C-449E-BD5B-480E1666FCB5

Q35655989-1CA5E507-80A0-4F7D-8C70-549E18DD74B1

Q35655989-1E5A91DD-D919-4228-AF6C-B5CD61FC6450

Q35655989-205B3A7B-46DC-4E68-A94C-CE58AB6A26EF

Q35655989-3AF2C9CD-E337-4DE5-B8F3-4962AF3DDDC2

Q35655989-5A763044-F805-4112-A8B9-8C12F86FCBE9

P304

Q35655989-6926827E-0C7D-44F2-A6C4-45AD807EB913

P31

Q35655989-24B88DBB-8283-42E3-9EA7-7EBD810E402E

P356

Q35655989-CF14235B-BB8E-4D17-8A80-B0DB6E0E6316

P407

Q35655989-D10798BF-F01D-4921-95E0-DA7092FB38C0

P433

Q35655989-17810BDC-D4FD-4893-A507-95C2FAD4F75F

P478

Q35655989-72C30E70-9EBA-4B76-8CE0-124F4752EA57

P50

Q35655989-066BC940-3520-4790-966D-CD16F51B4131

P577

Q35655989-E84DBF23-2F61-4FD2-8A7F-DCF58E43655A

P5875

Q35655989-747285E9-6919-4962-BD33-9DA31C163550

P698

Q35655989-0B51648E-CAA4-49C2-B009-5601BE045B8E

P932

Q35655989-577E4193-5834-48C4-B513-1E5CE2DE7936

P356

J.GASTRO.2015.02.008

P1433

Gastroenterology

P1476

Larazotide acetate for persist ...... a randomized controlled trial

@en

P2093

Anthony DiMarino

http://www.w3.org/2001/XMLSchema#string

Chao Wang

http://www.w3.org/2001/XMLSchema#string

Ciaran P Kelly

http://www.w3.org/2001/XMLSchema#string

Daniel A Leffler

http://www.w3.org/2001/XMLSchema#string

Henrik Rasmussen

http://www.w3.org/2001/XMLSchema#string

Joseph A Murray

http://www.w3.org/2001/XMLSchema#string

Natalie M Bachir

http://www.w3.org/2001/XMLSchema#string

Peter H R Green

http://www.w3.org/2001/XMLSchema#string

Premysl Bercik

http://www.w3.org/2001/XMLSchema#string

Wendy Perrow

http://www.w3.org/2001/XMLSchema#string

P2860

The Oslo definitions for coeliac disease and related terms

Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3

Alterations of the intestinal transport and processing of gliadin peptides in celiac disease.

Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet

Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology.

Gluten-free diet and quality of life in patients with screen-detected celiac disease.

Patient perception of treatment burden is high in celiac disease compared with other common conditions

Alterations in intestinal permeability.

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.

The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study.

P304

1311-9.e6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2015.02.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P50

Richard N. Fedorak

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272240051

http://www.w3.org/2001/XMLSchema#string

P698

25683116

http://www.w3.org/2001/XMLSchema#string

P932

4446229

http://www.w3.org/2001/XMLSchema#string